Update of MERS-CoV rapid risk assessment following large South Korean cluster
In this updated rapid risk assessment, ECDC’s assessment continues to be that the MERS-CoV outbreak poses a low risk to the EU and highlights the importance of rapid consideration of MERS-CoV and infection control measures in healthcare settings.
The evolving cluster of Middle East respiratory syndrome coronavirus (MERS-CoV) in South Korea is the largest of its kind outside of the Middle East. Travel associated MERS-CoV infections, such as the primary case in the South Korean cluster, are not unexpected nor are instances of secondary infections. It is the scale of this cluster and that an infected person travelled to China that makes this particularly noteworthy. However, ECDC’s assessment continues to be that the MERS-CoV outbreak poses a low risk to the EU and highlights the importance of rapid consideration of MERS-CoV and infection control measures in healthcare settings.
Risk to travellers to South KoreaThe South Korean cluster has affected patients, visitors of patients and healthcare workers in a few healthcare facilities and close relatives of the cases. The outbreak so far does not represent an increased risk of infection for travellers or visitors to South Korea. However, patients who present with severe acute respiratory disease in the EU and have recently been in contact with healthcare services in South Korea should be considered for assessment for MERS-CoV, similar to patients having been in contact with healthcare services in the Middle East.
WHO has stated that there is currently no indication that the virus is behaving differently to how it has behaved in the past and that there is no indication of sustained transmission from person to person. However, further details of the virus characterisation in South Korea are pending.
Surveillance and infection control essentialInternational surveillance for MERS-CoV cases among travellers remains essential due to the continued risk of an infected person travelling to Europe after exposure in the Middle East. Moreover rapid efforts to contain nosocomial clusters are vital to prevent broader transmission. Although sustained human-to-human transmission is unlikely, secondary transmission to unprotected close contacts remains a risk, especially in healthcare settings, as now documented in South Korea.
Systematic implementation of infection control measures in hospital settings is essential to interrupt transmission and prevent clusters of healthcare-associated infection. The challenges of detecting rare imported cases of respiratory infection early on highlight the need for eliciting travel history from patients and adequate infection prevention and control measures for all patients showing symptoms of acute respiratory infection.
Since the previous update of the Rapid Risk Assessment dated 8 March 2015, there have been 129 new cases and 53 additional deaths from MERS-CoV reported globally: Saudi Arabia (81 cases and 48 deaths), Qatar (3 cases and one death), Oman (one case) United Arab Emirates (two cases), Iran (one case) South Korea (40 cases and four deaths) and China (one case).
- Rapid risk assessment on severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV). 16th update, 5 June 2015
- Factsheet on MERS-CoV, also provides overview of case management and treatment measures
- Coronavirus health topic page
- Latest epidemiological information reported in the weekly Communicable Disease Threat Report
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.Read more
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more
Epidemiological update: Review of influenza season 2016–2017 in the EU/EEA
The influenza season 2016–2017 has now come to an end in Europe. In week 17/2017, all EU/EEA countries reported low influenza activity and the positivity rate (proportion of influenza virus positives among all tested specimens) falling below the 10% benchmark to 9.9%. For the previous six weeks, almost all EU/EEA countries had reported low influenza activity.Read more